Biliary tract cancer refers to various types of cancer that ... and about half were male. The study included people of different racial backgrounds: Asian (56%), White (37%), Black or African ...

Background: The presence of infective microorganisms in the bilio-pancreatic tract is believed to be important in both the onset and outcome of acute biliary pancreatitis. In this study, the ...

Background and methods. Biliary tract cancer is a heterogenous group of malignancies, which include gallbladder cancer, extrahepatic cholangiocarcinoma and intrahepatic cholangiocarcinoma.

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

"Biliary tract cancer is comparatively rare, but it's aggressive and spreads fast. Our accrual of more than 450 patients in a little more than two years really shows there is a need for new ways ...

Key Takeaways. Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial.

One of the deadliest forms of cancer is biliary tract cancer. Only one in three patients diagnosed with the disease is operable. The rest must settle for life-sustaining treatment.

Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa.

Today we finally heard the data from the much-awaited abstract, examining gemcitabine, cisplatin, and Abraxane as compared to gemcitabine and cisplatin in first-line biliary tract cancers. This ...

Oncology/Hematology > Other Cancers FDA Approves Zanidatamab for Biliary Tract Cancer — New antibody indicated for previously treated, unresectable or metastatic HER2-positive disease ...